GlaxoSmithKline has won FDA approval for its drug designed to treat chronic obstructive pulmonary disease.

The disease, which affects 20 million of people and is associated with chronic bronchitis, will be treated with Advair Diskus 250/50, GSK said Tuesday. The drug is designed to be administered twice daily, but GSK said it is not intended as a replacement for inhalers.

Advair Diskus combines an anti-inflammatory and long-acting bronchodilator for the first time, GSK said.